United Therapeutics Co. Expected to Earn Q1 2024 Earnings of $5.93 Per Share (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Analysts at Leerink Partnrs lifted their Q1 2024 earnings estimates for shares of United Therapeutics in a research report issued on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will post earnings of $5.93 per share for the quarter, up from their prior forecast of $5.90. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2024 earnings at $6.32 EPS and Q3 2024 earnings at $7.04 EPS.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.67 EPS.

A number of other brokerages also recently issued reports on UTHR. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. HC Wainwright reissued a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, Wells Fargo & Company lifted their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.67.

United Therapeutics Price Performance

United Therapeutics stock opened at $237.93 on Thursday. The stock’s 50 day moving average is $231.71 and its 200 day moving average is $228.55. United Therapeutics has a one year low of $204.44 and a one year high of $261.54. The firm has a market cap of $11.20 billion, a P/E ratio of 11.99 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28.

Insiders Place Their Bets

In related news, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the sale, the director now directly owns 5,373 shares in the company, valued at $1,277,699.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $237.91, for a total transaction of $856,476.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,928.30. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the sale, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 129,790 shares of company stock valued at $30,528,633. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of United Therapeutics by 5.4% during the 1st quarter. BlackRock Inc. now owns 4,751,961 shares of the biotechnology company’s stock valued at $1,064,249,000 after buying an additional 241,594 shares during the last quarter. Vanguard Group Inc. boosted its position in United Therapeutics by 0.4% during the third quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock worth $1,053,212,000 after purchasing an additional 20,373 shares during the period. State Street Corp boosted its position in United Therapeutics by 4.5% during the second quarter. State Street Corp now owns 1,875,758 shares of the biotechnology company’s stock worth $414,074,000 after purchasing an additional 80,656 shares during the period. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 73.7% in the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of United Therapeutics by 14.9% in the first quarter. Geode Capital Management LLC now owns 759,143 shares of the biotechnology company’s stock valued at $169,811,000 after purchasing an additional 98,267 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.